Interview with AnaptysBio CEO in Japanese pharma publication Beikoku Seiyaku Gyokai Shuho
May 2010
“Leveraging a Novel Platform for Antibody Generation”
Read more »»
Roche discusses AnaptysBio deal in BioCentury Article
January 2010
“The potential of the [SHM platform] to provide medical differentiation
is what is important.” Eric de la Fortelle, Roche
Read more »»
AnaptysBio featured in R&D Focus Drug News
May 2009
Founded in 2005 and located in San Diego (USA), AnaptysBio
uses somatic hypermutation (SHM) for antibody discovery
and optimization.
Read more »»